Engineering stable cytoplasmic intrabodies with designed specificity

被引:30
作者
Donini, M
Morea, V
Desiderio, A
Pashkoulov, D
Villani, ME
Tramontano, A
Benvenuto, E
机构
[1] ENEA, UTS Biotecnol, Sez Genet & Genom Vegetale, I-00100 Rome, Italy
[2] CNR, Ist Biol & Patol Mol, I-00185 Rome, Italy
[3] Univ Roma La Sapienza, Dipartimento Sci Biochim Rossi Fanelli, I-00185 Rome, Italy
关键词
scFv fragment; intrabodies; cytoplasmic stability; antibody engineering; specificity grafting;
D O I
10.1016/S0022-2836(03)00530-8
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Many attempts have been made to develop antibody fragments that can be expressed in the cytoplasm ("intrabodies") in a stable and functional form. The recombinant antibody fragment scFv(F8) is characterised by peculiarly high in vitro stability and functional folding in both prokaryotic and eukaryotic cytoplasm. To dissect the relative contribution of different scFv(F8) regions to cytoplasmic stability and specificity we designed and constructed five chimeric molecules (scFv-P1 to P5) in which several groups of residues important for antigen binding in the poorly stable anti-hen egg lysozyme (HEL) scFv(D1.3) were progressively grafted onto the scFv(F8) scaffold. All five chimeric scFvs were expressed in a soluble form in the peri-plasm and cytoplasm of Escherichia coli. All the periplasmic oxidised forms and the scFv(P3) extracted from the cytoplasm in reducing conditions had HEL binding affinities essentially identical (K-d = 15 nM) to that of the cognate scFv(D1.3) fragment (K-d = 16 nM). The successful grafting of the antigen binding properties of D1.3 onto the scFv(F8) opens the road to the exploitation of this molecule as a scaffold for the reshaping of intrabodies with desired specificities to be targeted to the cytoplasm. (C) 2003 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:323 / 332
页数:10
相关论文
共 53 条
[31]   INHIBITION OF HIV-1 TAT-MEDIATED LTR TRANSACTIVATION AND HIV-1 INFECTION BY ANTI-TAT SINGLE-CHAIN INTRABODIES [J].
MHASHILKAR, AM ;
BAGLEY, J ;
CHEN, SY ;
SZILVAY, AM ;
HELLAND, DG ;
MARASCO, WA .
EMBO JOURNAL, 1995, 14 (07) :1542-1551
[32]   Conformations of the third hypervariable region in the VH domain of immunoglobulins [J].
Morea, V ;
Tramontano, A ;
Rustici, M ;
Chothia, C ;
Lesk, AM .
JOURNAL OF MOLECULAR BIOLOGY, 1998, 275 (02) :269-294
[33]   Antibody modeling: Implications for engineering and design [J].
Morea, V ;
Lesk, AM ;
Tramontano, A .
METHODS, 2000, 20 (03) :267-279
[34]   Radioactive labeling of recombinant antibody fragments by phosphorylation using human casein kinase II and [gamma-P-32]-ATP [J].
Neri, D ;
Petrul, H ;
Winter, G ;
Light, Y ;
Marais, R ;
Britton, KE ;
Creighton, AM .
NATURE BIOTECHNOLOGY, 1996, 14 (04) :485-490
[35]   Disrupting the hydrophobic patches at the antibody variable/constant domain interface: Improved in vivo folding and physical characterization of an engineered scFv fragment [J].
Nieba, L ;
Honegger, A ;
Krebber, C ;
Pluckthun, A .
PROTEIN ENGINEERING, 1997, 10 (04) :435-444
[36]   SYNTHESIS OF A FUNCTIONAL ANTIPHYTOCHROME SINGLE-CHAIN-FV PROTEIN IN TRANSGENIC TOBACCO [J].
OWEN, M ;
GANDECHA, A ;
COCKBURN, B ;
WHITELAM, G .
BIO-TECHNOLOGY, 1992, 10 (07) :790-794
[37]   Antibody scFv fragments without disulfide bonds made by molecular evolution [J].
Proba, K ;
Wörn, A ;
Honegger, A ;
Plückthun, A .
JOURNAL OF MOLECULAR BIOLOGY, 1998, 275 (02) :245-253
[38]   A natural antibody missing a cysteine in V-H: Consequences for thermodynamic stability and folding [J].
Proba, K ;
Honegger, A ;
Pluckthun, A .
JOURNAL OF MOLECULAR BIOLOGY, 1997, 265 (02) :161-172
[39]   RESHAPING HUMAN-ANTIBODIES FOR THERAPY [J].
RIECHMANN, L ;
CLARK, M ;
WALDMANN, H ;
WINTER, G .
NATURE, 1988, 332 (6162) :323-327
[40]   GENERAL METHOD FOR MAXIMIZING THE EXPRESSION OF A CLONED GENE [J].
ROBERTS, TM ;
KACICH, R ;
PTASHNE, M .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1979, 76 (02) :760-764